Randomized phase <scp>III</scp> study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (<scp>KHBO1401</scp>‐ <scp>MITSUBA</scp>)Tatsuya Ioka, Masashi Kanai, Shogo Kobayashi et al.|Journal of Hepato-Biliary-Pancreatic Sciences|2022Cited by 244
Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA)Daisuke Sakai, Tatsuya Ioka, Yoshihumi Takeyama et al.|Annals of Oncology|2018Cited by 109
Antimicrobial susceptibility of pathogens isolated from surgical site infections in Japan: Comparison of data from nationwide surveillance studies conducted in 2010 and 2014–2015Yoshio Takesue, Katsunori Yanagihara, Shinya Kusachi et al.|Journal of Infection and Chemotherapy|2017Cited by 51
Antimicrobial susceptibility of common pathogens isolated from postoperative intra-abdominal infections in JapanYoshio Takesue, Katsunori Yanagihara, Shinya Kusachi et al.|Journal of Infection and Chemotherapy|2018Cited by 37
Corrigendum to “Antimicrobial susceptibility of common pathogens isolated from postoperative intra-abdominal infections in Japan” [J Infect Chemother 24 (2018) 330–340]Yoshio Takesue, Katsunori Yanagihara, Shinya Kusachi et al.|Journal of Infection and Chemotherapy|2018Cited by 3